ODI Pharma AB publishes outcome of rights issue
The subscription period in ODI Pharma AB’s ("ODI" or the "Company") issue of shares with preferential right (the “Rights Issue”) ended on December 10, 2024. The Rights Issue was subscribed to a total of approximately 54.8 percent, including pre-subscription commitments. ODI will thus be provided proceeds of approximately SEK 2.2 million before deduction of transaction related costs.Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 2.2 million including pre-subscription commitments of approximately SEK 2.0 million, which corresponds to a